Home  /  Resource Library  /  Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Results of a phase I trial investigating vorinostat combined with sirolimus or everolimus for treatment of relapsed Hodgkin lymphoma. (Abstract only)